Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
49
resultados
Última actualización
31/08/2024 [08:34:00]
Resultados 25 a 49 de 49
Resumen de: WO2024155638A1
The present disclosure provides a method of manufacturing a biosensor for detecting a biomarker of Alzheimer's disease, comprising steps of depositing an aluminum oxide film on a Si substrate by an atomic layer deposition system to form an A12O3/Si substrate; depositing electrical contacts Cr/Au on the A12O3/Si substrate by a thermal evaporator to form a source, a drain and a planar gate on the A12O3/Si substrate; providing a bilayer graphene on the A12O3/Si substrate by thermal annealing under a vacuum environment; providing a bilayer graphene to a low-damage plasma treatment (LDPT) with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite on the A12O3/Si substrate; and immobilizing an antibody on a surface of the GO/G layered composite through a reaction between amine groups of the antibody and carboxyl groups of GO of the GO/G layered composites, wherein the antibody is specific for p-tau217 protein.
Resumen de: US2024085436A1
The present invention provides a kit of a related marker for a central neurodegenerative disease and a detection method thereof. The kit uses a double antibody sandwich detection method, and can simultaneously detect 5 Alzheimer disease-related proteins in the same sample. An A microsphere labeled with a rabbit antibody is adopted, shaking is conducted in an incubation process, and an incubating agent, including polyol, a polymer, a nonionic surfactant and a chelating agent, is added. The aforementioned components cooperate with each other to achieve a long-term effect of maintaining suspension of the microspheres, so as to promote the reaction in the incubation process, reduce the formation of microsphere agglomeration and reduce non-specific binding. The Fc fragment of a detection antibody is removed, and thus the interference with a non-specific reaction is excluded. The aforementioned improvements improve the accuracy in detection of the relevant proteins of Alzheimer disease, make the clinical detection application be more convenient, can reduce the cost of reagents and labor, and has strong specificity, high sensitivity and good repeatability, and thus has good application prospect.
Resumen de: ES2976116A1
An in vitro procedure to diagnose or determine the risk of developing Alzheimer's disease (AD) in a subject, this procedure quantifies the expression products of the LMNA and EMD genes in a sample of peripheral nerve or smooth muscle. (Machine-translation by Google Translate, not legally binding)
Resumen de: KR20240113650A
본 발명은 항-타우(tau) 단백질 항체 또는 이의 항원 결합 단편, 이를 코딩하는 핵산, 상기 핵산을 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체 또는 그의 항원 결합 단편의 제조방법, 이를 포함하는 퇴행성 뇌질환의 진단용 조성물에 관한 것이다.
Resumen de: KR20240113649A
본 발명은 항-베타 아밀로이드(Amyloid-beta, Aβ) 항체 또는 이의 항원 결합 단편, 이를 코딩하는 핵산, 상기 핵산을 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체 또는 그의 항원 결합 단편의 제조방법, 이를 포함하는 퇴행성 뇌질환의 진단용 조성물에 관한 것이다.
Resumen de: WO2024151904A2
This document provides methods and materials related to screening for and treating Alzheimer's disease (AD), including late-onset Alzheimer's disease (LOAD).
Resumen de: WO2024151839A1
Disclosed herein are methods for assaying a potential drug candidate for the treatment, prevention, reduction or amelioration of neurodegenerative diseases and disorders. Some aspects pertain to stimulating a cell to induce a phenotype characteristic of a neurodegenerative disease or disorder and contacting the cell with a potential drug candidate and determining a responsive change, wherein a decrease or loss in the phenotype is indicative that the drug candidate is capable of treating, preventing, reducing or ameliorating neurodegenerative diseases or disorders.
Resumen de: WO2024149703A1
Alzheimer disease (also termed Alzheimer's disease or AD) is a progressive and devastating neurodegenerative disorder with a poor prognosis, and for which no curative treatment is available yet With respect to diagnosis, a huge amount of work has been performed with the aim to identify relevant markers for diagnosing AD, ideally the different stages of progression thereof. It is admitted in the art that development of AD involves both genetic factors and non- genetic factors. This explains why the search for biomarkers includes identification of genetic and non-genetic biomarkers. Further, even though the field of Alzheimer disease research has rapidly developed over the last decade, there is still a lack of disease-modifying therapies. Thus, it remains a great need for methods allowing a diagnosis of the Alzheimer disease. The present disclosure relates to methods relating to the diagnosis of AD, including the development stage of AD, as well as methods for monitoring the efficiency of a (candidate) therapeutic treatment of AD, which methods take benefit from the inventors' findings that AD nucleated cells, especially AD skin fibroblasts, show one or more perinuclear crowns of the auto-phosphorylated form of the ATM protein.
Resumen de: US2024241124A1
The invention relates to nucleic acid-based sensors and their use in determining enzyme activity, disease detection, and monitoring the effectiveness of enzyme inhibitors.
Resumen de: WO2023034324A2
Described herein are methods for making and using antibodies that bind specifically to soluble oligomers of amyloid beta protein (oAβ), and methods of use thereof in diagnosis and treatment of diseases related to formation of pathogenic oligomers of oAβ. Also provided are T helper cell (Th) carrier peptides that can be conjugated to peptide immunogens to stimulate targeted humoral immune responses to the desired antigen.
Resumen de: CA3231228A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: EP4400841A1
The present invention relates to providing of a method of simply detecting Alzheimer's disease (AD) and a method of simply stratifying AD pathological phases, and providing of a reagent that can be used for the methods. Based on the fact that measurement of a protein contained in extracellular vesicles enables detection of Alzheimer's disease and stratification of AD pathological phases, the present invention provides the method of simply detecting Alzheimer's disease (AD), the method of simply stratifying AD pathological phases, and the reagent that can be used for the methods.
Resumen de: AU2022343929A1
The invention relates to biomarkers, and particularly, although not exclusively, to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to novel biomarkers for facilitating Braak staging for classifying the degree of pathology in Alzheimer's disease in living patients, and determining the need or otherwise of Positron Emission Topography (PET) scanning for detecting the presence of beta amyloid in the brain. The invention further provides diagnostic and prognostic methods and kits for neurodegenerative disorders, and for Braak staging and determining the need for conducting a PET scan on a subject suspected of suffering from Alzheimer's disease.
Resumen de: CA3231278A1
The present disclosure provides multicellular culture models for the study of neuroinflammation, such as to identify novel targets, biomarkers, and therapeutic agents for the diagnosis, prognosis, and treatment of neurodegenerative diseases. Further provided herein are assays for studying neuroinflammation using the present cell culture models.
Resumen de: CA3225302A1
Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: US2024230682A1
A method for analyzing a neurogranin-related peptide contained in a biological sample includes, in the stated order: a binding step of bringing the biological sample into contact with a carrier in a binding solution to obtain a bound body in which the neurogranin-related peptide is bound to the carrier; a washing step of washing the bound body using a washing solution; an elution step of bringing the bound body into contact with an acidic solution to obtain an eluate in which the neurogranin-related peptide is eluted in the acidic solution; and a detection step of detecting the neurogranin-related peptide in the eluate by mass spectrometry. Both the binding solution and the washing solution contain a surfactant, and the number of carbon atoms of a hydrophobic group of each surfactant is 9 or more and 11 or less.
Resumen de: US2024230678A1
The present invention refers to p53 sequence and post translational modifications (PTMs) and to their use as biomarkers in the diagnosis of neurodegenerative disease and cognitive decline and/or in the prognosis of Alzheimer's disease at different stages and/or of neurodegenerative disease in a biological sample. The invention also provides for a 1) diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of neurodegenerative disease, including Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), fronto-temporal dementia (FTD), Lewi's Body (LB), and vascular dementia (VD) in a subject, by evaluating the PTMs to the said p53 linear sequence protein and possible cut of its full sequence specifically in human plasma of patients; and 2) prognosis of AD in CU and MCI patients.
Resumen de: WO2024148357A2
U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.
Resumen de: KR20240108272A
본 발명은 알파-시누클레인에 의한 혈액-뇌장벽 손상 진단용 마커 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 ADAM8, C1S, C3, CCL2, CCL20, CCL5, CD83, CSF2, CSF3, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, EBI3, IL1B, KYNU, LTB, MMP10, PAPLN, TNC, TNFRSF9 및 VNN1으로 이루어진 군 중에서 선택되는 하나 이상의 유전자의 mRNA 또는 상기 유전자의 단백질을 포함하는 알파-시누클레인에 의한 혈액-뇌 장벽(BBB) 손상 진단용 마커 조성물, 상기 본 발명의 마커 유전자에 대한 mRNA 또는 이의 단백질 수준을 측정하는 물질을 포함하는 알파-시누클레인병증 진단용 조성물, 알파-시누클레인병증 진단키트 및 (a) 환자로부터 분리된 생물학적 시료로부터 상기 본 발명의 마커 유전자의 mRNA 또는 이의 단백질 발현양을 측정하는 단계; 및 (b) 정상 대조군 시료로부터 상기 유전자의 mRNA 또는 단백질 발현양을 측정하여 상기 (a) 단계의 측정 결과와 비교하는 단계를 포함하는 알파-시누클레인병증을 예측 또는 진단하기 위한 정보제공방법에 관한 것이다.
Resumen de: AU2022343929A1
The invention relates to biomarkers, and particularly, although not exclusively, to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to novel biomarkers for facilitating Braak staging for classifying the degree of pathology in Alzheimer's disease in living patients, and determining the need or otherwise of Positron Emission Topography (PET) scanning for detecting the presence of beta amyloid in the brain. The invention further provides diagnostic and prognostic methods and kits for neurodegenerative disorders, and for Braak staging and determining the need for conducting a PET scan on a subject suspected of suffering from Alzheimer's disease.
Resumen de: US2024218034A1
Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.
Resumen de: AU2022408967A1
Described herein are improvements relating to IGF-1 function analysis, adjustment and its application in disease management of non-neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) and/or cGP/IGF-1 molar ratio as the plasma biomarker for prediction of risk and recovery of non-neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing animal, marine or fungal based material such as concentrate/extract of hydrolysed bovine collagen and marine collagen, mushroom and seaweed along with plant-based cGPMAX™ for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 molar ratio along with a means to adjust and normalise cGP and cGP/IGF-1 molar ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data. Supplementation of bovine collagen formulated cGPMAXTM effectively improved the sensory function in patients with diabetic neuropathy.
Resumen de: US2024222102A1
Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Nº publicación: JP2024088689A 02/07/2024
Solicitante:
ヤンセンバイオテツク，インコーポレーテツド
Resumen de: CN117209599A
Monoclonal anti-PHF-tau antibodies and antigen binding fragments thereof are described herein. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies to treat or prevent disorders, such as tauopathies.
BOPI
Sede Electrónica
